Keytruda RCC Approval/I-O – Toni Choueiri, MD, and Robert Figlin, MD, discuss the recent Keytruda approval in renal cell carcinoma (RCC)

Keytruda RCC Approval/I-O – Toni Choueiri, MD, and Robert Figlin, MD, discuss the recent Keytruda approval in renal cell carcinoma (RCC)

Thursday May 16, 2019

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Toni Choueiri, MD, Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute, discuss Keytruda's approval in renal cell carcinoma (RCC).

Featured Videos

Véronique Diéras, MD, on the optimal setting in which to receive a PARP inhibitor

Banu Arun, MD, regarding veliparib in breast cancer patients with BRCA mutations

Shirish M. Gadgeel MBBS, speculates on the future of RET-altered NSCLC